Infections following rejection therapies in kidney and liver transplant recipients

• Published in: Transplant infectious disease Vol. 24; no. 6; pp. e13981 - n/a
• Main Authors: Gupta, Simran, Gea‐Banacloche, Juan, Me, Hay‐Me, Chascsa, David M. H., Heilman, Raymond L., Budhiraja, Pooja, Yaman, Reena N., Vikram, Holenarasipur R., Zhang, Nan, Joseph, Anna M., Kodali, Lavanya
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.12.2022
• Subjects: acute rejection; Bacteremia; Complications; Cytomegalovirus; Female; Females; Gender; Graft rejection; Graft Rejection - drug therapy; Graft Rejection - prevention & control; Health risks; Humans; Immunosuppressive Agents - therapeutic use; Infections; Kidney; kidney transplant; Kidney transplantation; Kidney transplants; Kidneys; Leukocytes (neutrophilic); Liver; liver transplant; Liver transplantation; Liver Transplantation - adverse effects; Liver transplants; Mortality; Neutrophils; opportunistic infections; Organ Transplantation - adverse effects; Prophylaxis; Rejection; Retrospective Studies; Risk analysis; Risk factors; solid organ transplant; Transplant Recipients; Viremia; Viruses; infections; kidney transplant; opportunistic infections; acute rejection; liver transplant; solid organ transplant
• ISSN: 1398-2273; 1399-3062
• DOI: 10.1111/tid.13981

Introduction Infections are known complications of solid‐organ transplant. Treatment for rejection may increase risk of infection. We aimed to study frequency of infection and identify the risk factors for infections in solid organ transplant (SOT) (liver and kidney) recipients treated for rejection. Methods This is a retrospective chart review of all liver and kidney transplant recipients treated for rejection at our institution from 2014 to 2020. We collected information on episodes of acute rejection in the first year of transplant and infections within 6 months following rejection treatment. Results We identified 257 transplant patients treated for rejection. One hundred twelve (43.6%) developed infections, with a total of 226 infections. Urinary tracts infections were the most common, 72 (31.9%), followed by cytomegalovirus viremia in 37 (16.4%), bacteremia in 24 (10.6%), and BK virus in 14 (6.2%). Female sex (p = .047), elevated neutrophil count at rejection (p = .002), and increased number of rejection episodes (p = .022) were predictors of infection in kidney and simultaneous liver‐kidney recipients. No specific type of induction or rejection therapy was identified as a risk factor for infection, likely due to the prophylaxis protocols at our institution. Infection post rejection treatment was associated with higher graft loss (p = .021) and mortality (p = .031) in kidney transplant recipients. Conclusions Infections are common complications after treatment of SOT rejection. Female gender, higher neutrophil at time of rejection, and increased numbers of rejection episodes were predictors of infections after rejection in simultaneous liver‐kidney and kidney transplant patients. Infections were predictors of graft loss at 6 months and mortality at any point in follow‐up in kidney transplant patients.